Thanks for Nodus-ing: Basilea hands off preclinical oncology program for $248M in ongoing anti-infectives pivot

Looks like Basilea Pharmaceutica is getting closer to its final days as an oncology company.

The Switzerland-based Roche offshoot said Thursday that it had sold …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Thanks for Nodus-ing: Basilea hands off pre­clin­i­cal on­col­o­gy pro­gram for $248M in on­go­ing an­ti-in­fec­tives piv­ot